Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC)
Clinical trial NCT01333423 · WITHDRAWN
Trial details
- NCT number
- NCT01333423
- Sponsor
- M.D. Anderson Cancer Center
- Status
- WITHDRAWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2012-09-01
- Primary completion
- 2015-09-01
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.